New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
06:08 EDTADHDBioBlast said to be preparing $37.5M Nasdaq IPO, Globes reports
BioBlast Pharma, an Israeli drug development company, is preparing a $37.5M Nasdaq IPO, sources tell Globes. BioBlast founders Dr. Dalia Megiddo and Udi Gilboa took Alcobra Pharmaceuticals public in 2013, raising $25M last May and another $38M in a secondary offering in October. Reference Link
News For ADHD From The Last 14 Days
Check below for free stories on ADHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
06:25 EDTADHDAlcobra initiated with a Market Perform at FBR Capital
Subscribe for More Information
August 19, 2014
08:05 EDTADHDAlcobra announces enrollment of first patient in Phase IIb clinical trial of MDX
Alcobra announced that the first patient has been enrolled in a Phase IIb Fragile X study of MDX. The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013. The Phase IIb Fragile X trial is a multi-center, randomized, placebo-controlled study and is being conducted in 11 clinical sites, primarily in the U.S. It is designed to investigate MDX for 6 weeks compared with placebo in 60 adolescent and adult subjects with Fragile X Syndrome.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use